Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 600 of 672 entries
View as:

Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1

Phase: N/A Priority: Normal
NCT ID: NCT06532656 Org: User:
Start: 11/20/24 End: 08/31/28 Due: 08/31/29

Clinical Outcomes and Routine Management of Adults With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and Ireland

Phase: N/A Priority: Normal
NCT ID: NCT03582098 Org: User:
Start: 09/12/18 End: 03/26/19 Due: 03/26/20

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03901339 Org: User:
Start: 05/08/19 End: 10/20/23 Due: 10/20/24

Metabolic Impact Assessment of Tenofovir Disoproxil Fumarate on Non-HIV-1 Infected Healthy Adult Male Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT00648817 Org: User:
Start: 07/31/06 End: 12/31/07 Due: 12/31/08

Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis

Phase: N/A Priority: Normal
NCT ID: NCT06029972 Org: User:
Start: 12/05/23 End: 05/31/27 Due: 05/31/28

Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years

Phase: N/A Priority: Normal
NCT ID: NCT02616783 Org: User:
Start: 12/22/15 End: 03/21/18 Due: 03/21/19

Rollover Protocol Continued Access to Tenofovir Disoproxil Fumarate (TDF) for Subjects in Taiwan

Phase: N/A Priority: Normal
NCT ID: NCT01334567 Org: User:
Start: 08/31/10 End: 12/31/13 Due: 12/31/14

An Open-Label Study of Emtricitabine in Combination With Other Antiretroviral Agents in HIV Infected Pediatric Subjects

Phase: N/A Priority: Normal
NCT ID: NCT00642291 Org: User:
Start: 11/30/02 End: 07/31/04 Due: 07/31/05

CAMELLIA: Anti-CD47 Antibody Therapy in Haematological Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT02678338 Org: User:
Start: 11/30/15 End: 02/28/19 Due: 02/28/20

GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection

Phase: N/A Priority: Normal
NCT ID: NCT01435226 Org: User:
Start: 09/30/11 End: 07/31/13 Due: 07/31/14

Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults

Phase: N/A Priority: Normal
NCT ID: NCT02858401 Org: User:
Start: 01/29/15 End: 02/14/19 Due: 02/14/20

Efficacy and Safety of Sofosbuvir Plus Ribavirin in Adults With Chronic HCV Infection

Phase: N/A Priority: Normal
NCT ID: NCT02021643 Org: User:
Start: 12/10/13 End: 11/03/16 Due: 11/03/17

Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment

Phase: N/A Priority: Normal
NCT ID: NCT01818596 Org: User:
Start: 03/27/13 End: 07/18/18 Due: 07/18/19

The Safety and Effectiveness of Cidofovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS

Phase: N/A Priority: Normal
NCT ID: NCT00002437 Org: User:
Start: - End: - Due: -

Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed

Phase: N/A Priority: Normal
NCT ID: NCT02603120 Org: User:
Start: 11/11/15 End: 10/23/19 Due: 10/23/20

Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis

Phase: N/A Priority: Normal
NCT ID: NCT04112303 Org: User:
Start: 10/16/19 End: 06/25/21 Due: 06/25/22

Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05502237 Org: User:
Start: 10/12/22 End: 06/30/28 Due: 06/30/29

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05382299 Org: User:
Start: 07/20/22 End: 07/31/28 Due: 07/31/29

ADVANCE MPI 1: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)

Phase: N/A Priority: Normal
NCT ID: NCT00208299 Org: User:
Start: 10/31/03 End: 08/31/06 Due: 08/31/07

Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults

Phase: N/A Priority: Normal
NCT ID: NCT01968551 Org: User:
Start: 09/03/13 End: 07/09/16 Due: 07/09/17

Study of Obeldesivir as Postexposure Prophylaxis for Marburg Virus Disease

Phase: N/A Priority: Normal
NCT ID: NCT06682234 Org: User:
Start: 07/31/25 End: 07/31/25 Due: 07/31/26

Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

Phase: N/A Priority: Normal
NCT ID: NCT01533259 Org: User:
Start: 01/31/12 End: 07/31/13 Due: 07/31/14

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Evixapodlin (Formerly GS-4224) in Participants With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04049617 Org: User:
Start: 08/26/19 End: 03/30/21 Due: 03/30/22

Study of GS-1811 Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05007782 Org: User:
Start: 08/18/21 End: 12/31/27 Due: 12/31/28

Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT01799889 Org: User:
Start: 03/14/13 End: 01/30/20 Due: 01/30/21